These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22171556)

  • 21. [A frequent problem in the laboratory control of heparinization: contamination of blood specimens with exogenous heparin].
    Lämmle B; Noll G; Häuptli W; Tran TH; Luengo E; Lohri A; Ritz R; Duckert F
    Schweiz Med Wochenschr; 1984 Jun; 114(24):873-5. PubMed ID: 6740303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational approach to use of heparin during cardiac catheterization in children.
    Grady RM; Eisenberg PR; Bridges ND
    J Am Coll Cardiol; 1995 Mar; 25(3):725-9. PubMed ID: 7860920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of potency of heparin active pharmaceutical ingredient by near infrared reflectance spectroscopy.
    Sun C; Zang H; Liu X; Dong Q; Li L; Wang F; Sui L
    J Pharm Biomed Anal; 2010 Apr; 51(5):1060-3. PubMed ID: 20036090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Control of heparin and oral anticoagulants, with micromethods: thrombin time, quick determination with addition of protamine].
    Seiler K; Müller G; Duckert F
    Schweiz Med Wochenschr; 1970 Sep; 100(36):1522-8. PubMed ID: 5524716
    [No Abstract]   [Full Text] [Related]  

  • 27. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gabexate mesilate and heparin responsiveness in coronary patients.
    Ranucci M
    Med Sci Monit; 2004 Mar; 10(3):PI40-3. PubMed ID: 14976449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
    Ben-Hadj-Khalifa S; Hézard N; Almawi WY; Remy MG; Florent B; Mahjoub T; Nguyen P
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
    Chan AK; Berry LR; Monagle PT; Andrew M
    Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
    Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery.
    Bar-Yosef S; Cozart HB; Phillips-Bute B; Mathew JP; Grocott HP
    Can J Anaesth; 2007 Feb; 54(2):107-13. PubMed ID: 17272249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the sensitivity of an in vitro high frequency ultrasound device to monitor the coagulation process: study of the effects of heparin treatment in a murine model.
    Callé R; Rochefort GY; Desbuards N; Plag C; Antier D; Ossant F
    Ultrasound Med Biol; 2010 Feb; 36(2):295-305. PubMed ID: 20045589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
    Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid serum tube technology overcomes problems associated with use of anticoagulants.
    Zhao KN; Dimeski G; de Jersey J; Johnson LA; Grant M; Masci PP; Lavin MF
    Biochem Med (Zagreb); 2019 Oct; 29(3):030706. PubMed ID: 31624459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithrombin activity and prolongation of thrombin time; comparative study of heparin and of some synthetic heparinoids].
    BURSTEIN M; GUINAND A
    Arch Int Pharmacodyn Ther; 1955 Jun; 102(1-2):96-104. PubMed ID: 13239250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.